Table 3.

Efficacy results for RAS wild-type PRIME, PEAK and 20050181 panitumumab trial patients according to primary tumour location

	PRIME (RAS wt)				PEAK (RAS wt/BRAF wt)				20050181 (second-line setting) (RAS wt)
	Right-sided N=88		Left-sided N=328		Right-sided N=36		Left-sided N=107		Right-sided N=70		Left-sided N=298
Parameter	FOLFOX4	FOLFOX4 +pani	FOLFOX4	FOLFOX4 +pani	FOLFOX6 +bev	FOLFOX6 +pani	FOLFOX6 +bev	FOLFOX6 +pani	FOLFIRI	FOLFIRI +pani	FOLFIRI	FOLFIRI +pani
	n = 49	n = 39	n = 159	n = 169	n = 14	n = 22	n = 54	n = 53	n = 39	n = 31	n = 148	n = 150
OS
Median, months	15.4	11.1	23.6	30.3	21.04	17.4	32.0	43.4	8.1	10.3	16.6	20.1
HR (95.5% CI)a	0.87 (0.55–1.37)		0.73 (0.57–0.93)		0.67 (0.30–1.50)		0.77 (0.46–1.28)		1.14 (0.68–1.89)		0.96 (0.75–1.23)
P value	0.55		0.012		0.32		0.31		0.62		0.75
P value for interaction	0.51				0.77				0.55
PFS
Median, months	7.0	7.5	9.2	12.9	12.6	8.7	11.5	14.6	2.4	4.8	5.8	8.0
HR (95.5% CI)a	0.80 (0.51–1.26)		0.72 (0.57–0.90)		1.04 (0.50–2.18)		0.68 (0.45–1.04)		0.75 (0.45–1.27)		0.88 (0.69–1.12)
P value	0.33		0.005		0.91		0.07		0.28		0.30
P value for interaction	0.68				0.32				0.58
ORR
Rate, %	34.8	42.1	52.6	67.9	50.0	63.6	57.4	64.1	2.6	13.3	13.2	49.7
OR (95.5% CI)	1.36 (0.60–3.08)		1.91 (1.33–2.72)		1.75 (0.57–5.41)		1.33 (0.72–2.46)		5.69 (0.60–53.63)		6.49 (3.73–11.30)
P value	0.46		<0.001		0.33		0.37		0.13		<0.001
P value for interaction	0.46				0.67				0.91

^aHRs were adjusted for BRAF status, adjuvant chemotherapy and ECOG PS.

Bev, bevacizumab; CI, confidence interval; FOLFIRI, fluorouracil, leucovorin and irinotecan; FOLFOX, fluorouracil, leucovorin and oxaliplatin; HR, hazard ratio; OR, odds ratio: ORR, objective response rate; OS, overall survival; pani, panitumumab; PFS, progression-free survival; wt, wild-type.